Schmid M, Kreil A, Jessner W, Homoncik M, Datz C, Gangl A, Ferenci P, Peck-Radosavljevic M
Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Währingergürtel 18-20, A-1090 Vienna, Austria.
Gut. 2005 Jul;54(7):1014-20. doi: 10.1136/gut.2004.057893.
Treatment of chronic hepatitis C with interferon (IFN)-alpha and ribavirin has haematotoxic effects. We evaluated the effects of four different IFN/IFN-ribavirin treatment regimens on haematopoiesis.
Haematopoiesis was studied in 133 patients with chronic hepatitis C receiving IFN-alpha2b alone (group A) or in combination with ribavirin (group B), pegylated IFN-alpha2a (group C), or pegylated IFN-alpha2b (group D) in combination with ribavirin.
At week 4, haemoglobin levels were diminished in all groups receiving combination therapy. In the monotherapy group, haemoglobin decreased slightly after eight weeks. In all groups, haemoglobin remained diminished throughout therapy. In all patients, leucocytes (while blood cells) decreased after four weeks and remained low during treatment. Platelets (peripheral platelet count (PPC)) were decreased in all groups after four weeks and remained below baseline levels during therapy in group A, C, and D whereas in group B PPC recovered early and reached baseline levels at week 16 of therapy. Concomitantly with the decreases in haemoglobin and PPC, erythropoietin increased in all groups receiving combination therapy and thrombopoietin in all groups. Patients treated with pegylated IFN-alpha2a and those who received pegylated IFN-alpha2b combination therapy differed only in leucopoiesis, whereas erythropoiesis and thrombopoiesis were comparable.
IFN-alpha based therapies are associated with a decrease in all three haematopoietic lineages, irrespective of the type of therapy used. The stronger suppressive effect of pegylated IFN-alpha2a on leucopoiesis could be due to a dose effect. Overall, concentrations of endogenous haematopoietic growth factors are increased but can only partially alleviate haematotoxicity. Potential uses of exogenous haematopoietic growth factors and their impact on the virological response need to be explored.
使用干扰素(IFN)-α和利巴韦林治疗慢性丙型肝炎具有血液毒性作用。我们评估了四种不同的IFN/IFN-利巴韦林治疗方案对造血的影响。
对133例慢性丙型肝炎患者的造血情况进行了研究,这些患者单独接受IFN-α2b(A组)或与利巴韦林联合使用(B组)、聚乙二醇化IFN-α2a(C组)或聚乙二醇化IFN-α2b(D组)与利巴韦林联合使用。
在第4周时,所有接受联合治疗的组血红蛋白水平均降低。在单药治疗组中,8周后血红蛋白略有下降。在所有组中,整个治疗过程中血红蛋白一直降低。在所有患者中,白细胞(血细胞)在4周后减少,并在治疗期间一直保持较低水平。4周后所有组的血小板(外周血小板计数(PPC))均降低,在A、C和D组治疗期间血小板计数一直低于基线水平,而在B组中PPC恢复较早,并在治疗第16周时达到基线水平。与血红蛋白和PPC降低同时,所有接受联合治疗的组促红细胞生成素增加,所有组血小板生成素增加。接受聚乙二醇化IFN-α2a治疗的患者与接受聚乙二醇化IFN-α2b联合治疗的患者仅在白细胞生成方面存在差异,而红细胞生成和血小板生成情况相当。
基于IFN-α的治疗与所有三个造血谱系的减少有关,无论使用何种治疗类型。聚乙二醇化IFN-α2a对白细胞生成的抑制作用更强可能是由于剂量效应。总体而言,内源性造血生长因子浓度增加,但只能部分减轻血液毒性。需要探索外源性造血生长因子的潜在用途及其对病毒学应答的影响。